Heck Capital Advisors LLC Acquires New Stake in Johnson & Johnson (NYSE:JNJ)

Heck Capital Advisors LLC bought a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 7,661 shares of the company's stock, valued at approximately $1,108,000.

Several other hedge funds have also recently made changes to their positions in JNJ. Sulzberger Capital Advisors Inc. bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $453,000. Oregon Pacific Wealth Management LLC purchased a new position in Johnson & Johnson during the fourth quarter worth about $949,000. Horan Securities Inc. grew its position in Johnson & Johnson by 1.3% during the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock worth $1,038,000 after buying an additional 90 shares in the last quarter. Strategic Financial Concepts LLC grew its position in Johnson & Johnson by 57.9% during the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company's stock worth $501,000 after buying an additional 1,271 shares in the last quarter. Finally, State of Wyoming grew its position in Johnson & Johnson by 205,580.0% during the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after buying an additional 10,279 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Up 0.4%

Shares of NYSE:JNJ traded up $0.60 during trading on Thursday, hitting $153.03. The stock had a trading volume of 2,531,513 shares, compared to its average volume of 7,931,998. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a market capitalization of $368.20 billion, a PE ratio of 23.03, a PEG ratio of 2.56 and a beta of 0.42. The firm's fifty day moving average is $154.63 and its 200 day moving average is $153.64. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a $1.30 dividend. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.40%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Barclays cut their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their target price for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Finally, Morgan Stanley boosted their target price on Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 16th. Eleven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.